ArcherDx Raises $35M in Preferred Series A Round

Mar 20, 2018

|

NEW YORK (Genomeweb) – ArcherDx said today that it has closed a $35 million Series A round of preferred financing.

The round was led by Boulder Ventures and PBM Capital Group, and included new investors Longwood Fund and Peierls Foundation. In conjunction with the financing, Boulder Ventures Founder and General Partner Kyle Lefkoff has joined ArcherDx's board.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

ArcherDx Raises $35M in Preferred Series A Round

To read the full story....

Breaking News

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Infectious Disease Test Firm Talis Biomedical Files for IPO

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

Sponsorships